Ignite Creation Date:
2024-05-05 @ 5:12 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00407576
Status:
COMPLETED
Last Update Posted:
2017-07-02
First Post:
2006-12-02
Brief Title:
PET Imaging of Brain Amyloid Using 11CMeS-IMPY
Sponsor:
National Institute of Mental Health NIMH
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
PET Imaging of Brain Amyloid Using 11CMeS-IMPY
Status:
COMPLETED
Status Verified Date:
2008-11-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Alzheimers disease is associated with accumulation in the brain of a protein called amyloid The purpose of this study is to test the ability of a research drug to measure amyloid in brain using positron emission tomography PET and a research drug called 11CMeS-IMPY
Detailed Description:
Alzheimers disease AD is characterized pathologically by the presence of beta-amyloid plaques in brain A substantial body of research indicates that the presence of increased beta -amyloid peptide is neurotoxic and may initiate further pathology observed in AD including neurofibrillary tangles synaptic loss and dysfunction and neurodegeneration There are multiple binding sites available on beta-amyloid plaques Three clearly identified sites are Congo-red type Thioflavin-T type and FDDNP type Radioligands currently under development using positron emission tomography PET for studying beta-amyloid in clinical research or drug development are based on Thioflavin-T site such as 11CPIB and 11CSB-13 Though variously effective these radioligands have one or more drawbacks with respect to measuring relative regional beta-amyloid densities Therefore we have recently developed 11CMeS-IMPY as an alternative radioligand for imaging beta-amyloid which will allow a more accurate quantification of amyloid plaques in AD brain In the current protocol we wish to evaluate 11CMeS-IMPY in both healthy subjects and AD patients to determine the kinetics of brain imaging beta-amyloid plaques in AD patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 07-M-0036 | None | None | None |